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The “Diagnostic Standards and Classification of Tuberculosis
in Adults and Children” is a joint statement prepared by the
American Thoracic Society and the Centers for Disease Con-
trol and endorsed by the Infectious Disease Society of America.
The Diagnostic Standards are intended to provide a framework
for and understanding of the diagnostic approaches to tuber-
culosis infection/disease and to present a classification scheme
that facilitates management of all persons to whom diagnostic
tests have been applied.
The specific objectives of this revision of the Diagnostic
Standards are as follows.
1. To define diagnostic strategies for high- and low-risk pa-
tient populations based on current knowledge of tuberculo-
sis epidemiology and information on newer technologies.
2. To provide a classification scheme for tuberculosis that is
based on pathogenesis. Definitions of tuberculosis disease









) coincide with the appropriate re-
sponse of the health care team, whether it be no response,










) provide the necessary information for




) provide a uni-
form, functional, and practical means of reporting. Because
tuberculosis, even after it has been treated adequately, re-
mains a pertinent and lifelong part of a person’s medical
history, previous as well as current disease is included in
the classification.
This edition of the Diagnostic Standards has been prepared
as a practical guide and statement of principles for all persons
involved in the care of patients with tuberculosis. References
have been included to guide the reader to texts and journal ar-




Tuberculosis remains one of the deadliest diseases in the world.
The World Health Organization (WHO) estimates that each
year more than 8 million new cases of tuberculosis occur and
approximately 3 million persons die from the disease (1). Ninety-
five percent of tuberculosis cases occur in developing coun-
tries, where few resources are available to ensure proper
treatment and where human immunodeficiency virus (HIV)
infection may be common. It is estimated that between 19 and





, the bacterium that causes tuberculosis infection
and disease (2).





 (3). Although the tuberculosis case
rate in the United States has declined during the past few





 Without application of effective
treatment for latent infection, new cases of tuberculosis can be
expected to develop from within this group.
Tuberculosis is a social disease with medical implications. It
has always occurred disproportionately among disadvantaged
populations such as the homeless, malnourished, and over-
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crowded. Within the past decade it also has become clear that
the spread of HIV infection and the immigration of persons
from areas of high incidence have resulted in increased num-
bers of tuberculosis cases.
 




Tuberculosis is spread from person to person through the air








 complex (4). Droplet nuclei are produced
when persons with pulmonary or laryngeal tuberculosis cough,
sneeze, speak, or sing. They also may be produced by aerosol
treatments, sputum induction, aerosolization during bron-
choscopy, and through manipulation of lesions or processing
of tissue or secretions in the hospital or laboratory. Droplet





are so small that air currents normally present in any indoor
space can keep them airborne for long periods of time (6).
Droplet nuclei are small enough to reach the alveoli within the
lungs, where the organisms replicate. Although patients with
tuberculosis also generate larger particles containing numer-
ous bacilli, these particles do not serve as effective vehicles for
transmission of infection because they do not remain airborne,
and if inhaled, do not reach alveoli. Organisms deposited on
intact mucosa or skin do not invade tissue. When large parti-
cles are inhaled, they impact on the wall of the upper airways,
where they are trapped in the mucous blanket, carried to the
oropharynx, and swallowed or expectorated (7).














) the concentration of organisms in the air deter-










) presumably the immune status of the exposed indi-
vidual. HIV-infected persons and others with impaired cell-





 after exposure than persons with
normal immunity; also, HIV-infected persons and others with
impaired cell-mediated immunity are much more likely to de-
velop disease if they are infected. However, they are no more





Techniques that reduce the number of droplet nuclei in a
given space are effective in limiting the airborne transmission of
tuberculosis. Ventilation with fresh air is especially important,
particularly in health care settings, where six or more room-air
changes an hour is desirable (9). The number of viable airborne
tubercle bacilli can be reduced by ultraviolet irradiation of air in
the upper part of the room (5). The most important means to
reduce the number of bacilli released into the air is by treating
the patient with effective antituberculosis chemotherapy (10). If
masks are to be used on coughing patients with infectious tu-
berculosis, they should be fabricated to filter droplet nuclei and
molded to fit tightly around the nose and mouth. Measures such
as disposing of such personal items as clothes and bedding, ster-
ilizing fomites, using caps and gowns and gauze or paper masks,
boiling dishes, and washing walls are unnecessary because they
have no bearing on airborne transmission.


















 is transmitted through the airborne route and there





penetrate the gastrointestinal mucosa or invade the lymphatic
tissue of the oropharynx when ingested in milk containing




has decreased significantly in developed countries as a result
of the pasteurization of milk and effective tuberculosis control


















 and is widely
used as a vaccine for tuberculosis. It may also be used as an
agent to enhance immunity against transitional-cell carcinoma
of the bladder. When used in this manner, adverse reactions




 BCG may be cultured from nonurinary tract system
specimens, i.e., blood, sputum, bone marrow, etc. (17).
 
III. PATHOGENESIS OF TUBERCULOSIS
 
After inhalation, the droplet nucleus is carried down the bron-
chial tree and implants in a respiratory bronchiole or alveolus.
Whether or not an inhaled tubercle bacillus establishes an in-
fection in the lung depends on both the bacterial virulence and
the inherent microbicidal ability of the alveolar macrophage
that ingests it (4, 18). If the bacillus is able to survive initial de-
fenses, it can multiply within the alveolar macrophage. The tu-
bercle bacillus grows slowly, dividing approximately every 25




has no known endotoxins or exotoxins; therefore, there is no
immediate host response to infection. The organisms grow for








 in number, which is suffi-
cient to elicit a cellular immune response (19, 20) that can be
detected by a reaction to the tuberculin skin test.
Before the development of cellular immunity, tubercle ba-
cilli spread via the lymphatics to the hilar lymph nodes and
thence through the bloodstream to more distant sites. Certain
organs and tissues are notably resistant to subsequent multi-
plication of these bacilli. The bone marrow, liver, and spleen
are almost always seeded with mycobacteria, but uncontrolled
multiplication of the bacteria in these sites is exceptional. Or-
ganisms deposited in the upper lung zones, kidneys, bones,
and brain may find environments that favor their growth, and
numerous bacterial divisions may occur before specific cellu-
lar immunity develops and limits multiplication.
In persons with intact cell-mediated immunity, collections
of activated T cells and macrophages form granulomas that





 are formed but do not appear to be
protective (21). The organisms tend to be localized in the cen-
ter of the granuloma, which is often necrotic (22). For the





 is arrested once cell-mediated immu-
nity develops, even though small numbers of viable bacilli may
remain within the granuloma. Although a primary complex
can sometimes be seen on chest radiograph, the majority of
pulmonary tuberculosis infections are clinically and radio-
graphically inapparent (18). Most commonly, a positive tuber-




 has taken place. Individuals with latent tuber-
culosis infection but not active disease are not infectious and
thus cannot transmit the organism. It is estimated that approx-
imately 10% of individuals who acquire tuberculosis infection
and are not given preventive therapy will develop active tu-
berculosis. The risk is highest in the first 2 yr after infection,
when half the cases will occur (23). The ability of the host to
respond to the organism may be reduced by certain diseases
such as silicosis, diabetes mellitus, and diseases associated with
immunosuppression, e.g., HIV infection, as well as by corti-
costeroids and other immunosuppressive drugs. In these cir-
cumstances, the likelihood of developing tuberculosisdisease
is greater. The risk of developing tuberculosis also appears to




AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 161 2000
 










; up to 50% of such persons may do










 (not treated) and then acquires HIV infection will
develop tuberculosis disease at an approximate rate of 5–10%
per year (25, 26).
In a person with intact cell-mediated immunity, the re-
sponse to infection with the tubercle bacillus provides protec-
tion against reinfection. The likelihood of reinfection is a func-
tion of the risk of reexposure, the intensity of such exposure,
and the integrity of the host’s immune system. In the United
States the risk of reexposure to an infectious case is low. Fur-
thermore, in an otherwise healthy, previously infected person,
any organisms that are deposited in the alveoli are likely to be
killed by the cell-mediated immune response. Exceptions may
occur, but in immunocompetent individuals, clinical and labo-
ratory evidence indicates that disease produced by the inha-
lation of a second infecting strain is uncommon. However,
reinfection has been documented to occur both in persons without
recognized immune compromise and in persons with advanced
HIV infection (27–29).
 
IV. CLINICAL MANIFESTATIONS OF TUBERCULOSIS
 
The clinical manifestations of tuberculosis are quite variable
and depend on a number of factors. Table 1 lists both host and
microbe-related characteristics as well as their interactions that
influence the clinical features of the disease. Before the begin-
ning of the epidemic of infection with HIV, approximately
85% of reported tuberculosis cases were limited to the lungs,
with the remaining 15% involving only nonpulmonary or both
pulmonary and nonpulmonary sites (30). This proportional dis-
tribution is substantially different among persons with HIV in-
fection. Although there are no national data that describe the
sites of involvement in HIV-infected persons with tuberculosis,
one large retrospective study of tuberculosis in patients with
advanced HIV infection reported that 38% had only pulmo-
nary involvement, 30% had only extrapulmonary sites, and
32% had both pulmonary and nonpulmonary involvement
(31). Moreover, extrapulmonary involvement tends to increase
in frequency with worsening immune compromise (32).
 
A. Systemic Effects of Tuberculosis
 
Tuberculosis involving any site may produce symptoms and
findings that are not specifically related to the organ or tissue
involved but, rather, are systemic in nature. Of the systemic ef-
fects, fever is the most easily quantified. The frequency with
which fever has been observed in patients with tuberculosis var-
ies from approximately 37 to 80% (33, 34). In one study (33),
21% of patients had no fever at any point in the course of hospi-
talization for tuberculosis. Of the febrile patients, 34% were
afebrile within 1 wk, and 64% in 2 wk, of beginning treatment.
The median duration of fever after beginning treatment was
10 d, with a range of 1 to 109 d. Loss of appetite, weight loss,
weakness, night sweats, and malaise are also common but are
more difficult to quantify and may relate to coexisting diseases.
The most common hematologic manifestations of tubercu-
losis are increases in the peripheral blood leukocyte count and
anemia, each of which occurs in approximately 10% of patients
with apparently localized tuberculosis (35, 36). The increase in
white blood cell counts is usually slight, but leukemoid reac-
tions may occur. Leukopenia has also been reported. An in-
crease in the peripheral blood monocyte and eosinophil counts
also may occur with tuberculosis. Anemia is common when the
infection is disseminated. In some instances, anemia or pancy-
topenia may result from direct involvement of the bone mar-
row and, thus, be a local, rather than a remote, effect.
Hyponatremia, which in one series was found to occur in
11% of patients (37), has been determined to be caused by
production of an antidiuretic hormone-like substance found
within affected lung tissue (38).
In many patients tuberculosis is associated with other seri-
ous disorders. These include HIV infection, alcoholism, chronic
renal failure, diabetes mellitus, neoplastic diseases, and drug
abuse, to name but a few. The signs and symptoms of these
diseases and their complications can easily obscure or modify
those of tuberculosis and result in considerable delays in diag-
nosis or misdiagnoses for extended periods of time, especially




Symptoms and physical findings
 
. Cough is the most common
symptom of pulmonary tuberculosis. Early in the course of the
illness it may be nonproductive, but subsequently, as inflam-
mation and tissue necrosis ensue, sputum is usually produced
and is key to most of our diagnostic methods. Hemoptysis may
rarely be a presenting symptom but usually is the result of pre-
vious disease and does not necessarily indicate active tubercu-
losis. Hemoptysis may result from residual tuberculous bron-
chiectasis, rupture of a dilated vessel in the wall of a cavity





 in the form of a mycetoma) in a residual cav-
ity, or from erosion of calcified lesions into the lumen of an
airway (broncholithiasis). Inflammation of the lung paren-
chyma adjacent to a pleural surface may cause pleuritic pain.
Dyspnea is unusual unless there is extensive disease. Tubercu-
losis may, however, cause severe respiratory failure (40, 41).
Physical findings in pulmonary tuberculosis are not gener-
ally helpful in defining the disease. Rales may be heard in the
area of involvement as well as bronchial breath sounds if there
is lung consolidation.
 
Radiographic features of pulmonary tuberculosis
 
. Pulmonary
tuberculosis nearly always causes abnormalities on the chest
 
TABLE 1
FACTORS THAT INFLUENCE THE CLINICAL FEATURES OF TUBERCULOSIS
 
Host Factors Microbial Factors
Host–Microbe
Interaction
Age Virulence of the organism Sites of involvement
Immune status Predilection (tropism) for specific tissues Severity of disease
Specificic immunodeficiency states
Malnutrition
Genetic factors (not yet defined)
Coexisting diseases
Immunization with bacillus Calmette-Guérin (BCG)
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film, although an endobronchial lesion may not be associated
with a radiographic finding. In addition, in patients with pulmo-
nary tuberculosis disease and HIV infection, a normal chest film
is more common than in persons with tuberculosis disease with-
out immune suppression. In primary tuberculosis occurring as a
result of recent infection, the process is generally seen as a mid-
dle or lower lung zone infiltrate, often associated with ipsilat-
eral hilar adenopathy. Atelectasis may result from compression
of airways by enlarged lymph nodes. This manifestation is more
common in children. If the primary process persists beyond the
time when specific cell-mediated immunity develops, cavitation
may occur (so-called “progressive primary” tuberculosis) (42).
Tuberculosis that develops as a result of endogenous reacti-
vation of latent infection usually causes abnormalities in the up-
per lobes of one or both lungs. Cavitation is common in this
form of tuberculosis. The most frequent sites are the apical and
posterior segments of the right upper lobe and the apical–poste-
rior segment of the left upper lobe. Healing of the tuberculous
lesions usually results in development of a scar with loss of lung
parenchymal volume and, often, calcification. In the immuno-
competent adult with tuberculosis, intrathoracic adenopathy is
uncommon but may occur, especially with primary infection. In
contrast, intrathoracic or extrathoracic lymphatic involvement is
quite common in children. As tuberculosis progresses, infected
material may be spread via the airways into other parts of the
lungs, causing a patchy bronchopneumonia. Erosion of a paren-
chymal focus of tuberculosis into a blood or lymph vessel may
lead to dissemination of the organism and a “miliary” (evenly
distributed small nodules) pattern on the chest film. Dissemi-
nated tuberculosis can occur in primary disease and may be an
early complication of tuberculosis in children (both immuno-
competent and immunocompromised). When it occurs in chil-





Old, healed tuberculosis presents a different radiologic ap-
pearance from active tuberculosis. Dense pulmonary nodules,
with or without visible calcification, may be seen in the hilar area
or upper lobes. Smaller nodules, with or without fibrotic scars,
are often seen in the upper lobes, and upper-lobe volume loss of-
ten accompanies these scars. Nodules and fibrotic lesions of old
healed tuberculosis have well-demarcated, sharp margins and are
often described as “hard.” Bronchiectasis of the upper lobes is a
nonspecific finding that sometimes occurs from previous pulmo-
nary tuberculosis. Pleural scarring may be caused by old tubercu-
losis but is more commonly caused by trauma or other infections.
Nodules and fibrotic scars may contain slowly multiplying tuber-
cle bacilli with significant potential for future progression to ac-
tive tuberculosis. Persons who have nodular or fibrotic lesions
consistent with findings of old tuberculosis on chest radiograph
and a positive tuberculin skin test reaction should be considered
high-priority candidates for treatment of latent infection regard-
less of age. Conversely, calcified nodular lesions (calcified granu-
loma) or apical pleural thickening poses a much lower risk for fu-
ture progression to active tuberculosis (42, 43).
In patients with HIV infection, the nature of the radio-
graphic findings depends to a certain extent on the degree of
immunocompromise produced by the HIV infection. Tuber-
culosis that occurs relatively early in the course of HIV infec-
tion tends to have the typical radiographic findings described
above (44, 45). With more advanced HIV disease the radio-
graphic findings become more “atypical”: cavitation is uncom-
mon, and lower lung zone or diffuse infiltrates and intratho-




Extrapulmonary tuberculosis usually presents more of a diag-
nostic problem than pulmonary tuberculosis. In part this re-
lates to its being less common and, therefore, less familiar to
most clinicians (46, 47). In addition, extrapulmonary tubercu-
losis involves relatively inaccessible sites and, because of the
nature of the sites involved, fewer bacilli can cause much
greater damage. The combination of small numbers of bacilli
and inaccessible sites causes bacteriologic confirmation of a
diagnosis to be more difficult, and invasive procedures are fre-
quently required to establish a diagnosis.
 
Extrapulmonary tuberculosis in HIV-infected patients
 
. Pre-
sumably, the basis for the high frequency of extrapulmonary
tuberculosis among patients with HIV infection is the failure





enabling hematogenous dissemination and subsequent in-
volvement of single or multiple nonpulmonary sites. Because
of the frequency of extrapulmonary tuberculosis among HIV-
infected patients, diagnostic specimens from any suspected
site of disease should be examined for mycobacteria. More-





 in patients who do not have an obvious localized site of




. Disseminated tuberculosis oc-
curs because of the inadequacy of host defenses in containing
tuberculous infection. This failure of containment may occur
in either latent or recently acquired tuberculous infection. Be-
cause of HIV or other causes of immunosuppression, the or-
ganism proliferates and disseminates throughout the body.
Multiorgan involvement is probably much more common than





tified in any specimen, other sites are not evaluated. The term
“miliary” is derived from the visual similarity of some dissemi-
nated lesions to millet seeds. Grossly, these lesions are 1- to
2-mm yellowish nodules that, histologically, are granulomas.
Thus disseminated tuberculosis is sometimes called “miliary”
tuberculosis. When these small nodules occur in the lung, the
resulting radiographic pattern is also termed “miliary.”
Because of the multisystem involvement in disseminated tu-
berculosis, the clinical manifestations are protean. The present-
ing symptoms and signs are generally nonspecific and are dom-
inated by systemic effects, particularly fever, weight loss, night
sweats, anorexia, and weakness (48–52). Other symptoms de-
pend on the relative severity of disease in the organs involved.
A productive cough is common because most patients with dis-
seminated disease also have pulmonary involvement. Head-
ache and mental status changes are less frequent and are usu-
ally associated with meningeal involvement (49). Physical
findings likewise are variable. Fever, wasting, hepatomegaly,
pulmonary findings, lymphadenopathy, and splenomegaly oc-
cur in descending order of frequency. A finding that is strongly
suggestive of disseminated tuberculosis is the choroidal tuber-
cle, a granuloma located in the choroid of the retina (53).
The chest film is abnormal in most but not all patients with
disseminated tuberculosis. In the series reported by Grieco
and Chmel (48), only 14 of 28 patients (50%) had a miliary
pattern on chest film, whereas 90% of 69 patients reported by
Munt (49) had a miliary pattern. Overall, it appears that at the
time of diagnosis approximately 85% of patients have the
characteristic radiographic findings of miliary tuberculosis.
Other radiographic abnormalities may be present as well.
These include upper lobe infiltrates with or without cavitation,
pleural effusion, and pericardial effusion. In patients with HIV
infection the radiographic pattern is usually one of diffuse in-




. Tuberculous lymphadenitis usually
presents as painless swelling of one or more lymph nodes. The
nodes involved most commonly are those of the posterior or an-
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quently the process is bilateral and other noncontiguous groups
of nodes can be involved (54). At least initially the nodes are dis-
crete and the overlying skin is normal. With continuing disease
the nodes may become matted and the overlying skin inflamed.
Rupture of the node can result in formation of a sinus tract,
which may be slow to heal. Intrathoracic adenopathy may com-
press bronchi, causing atelectasis leading to lung infection and
perhaps bronchiectasis. This manifestation is particularly com-
mon in children. Needle biopsy or surgical resection of the node
may be needed to obtain diagnostic material if the chest radio-
graph is normal and the sputum smear and culture are negative.
In persons not infected with HIV but with tuberculous lym-
phadenitis, systemic symptoms are not common unless there is
concomitant tuberculosis elsewhere. The frequency of pulmo-
nary involvement in reported series of patients with tubercu-
lous lymphadenitis is quite variable, ranging from approxi-
mately 5 to 70%. In HIV-infected persons lymphadenitis is




. There are two mechanisms by which
the pleural space becomes involved in tuberculosis. The differ-
ence in pathogenesis results in different clinical presentations,
approaches to diagnosis, treatment, and sequelae. Early in the
course of a tuberculous infection a few organisms may gain ac-
cess to the pleural space and, in the presence of cell-mediated
immunity, cause a hypersensitivity response (55, 56). Com-
monly, this form of tuberculous pleuritis goes unnoticed, and
the process resolves spontaneously. In some patients, how-
ever, tuberculous involvement of the pleura is manifested as
an acute illness with fever and pleuritic pain. If the effusion is
large enough, dyspnea may occur, although the effusions gen-
erally are small and rarely are bilateral. In approximately 30%
of patients there is no radiographic evidence of involvement
of the lung parenchyma; however, parenchymal disease is
nearly always present, as evidenced by findings of lung dissec-
tions (57).
The second variety of tuberculous involvement of the
pleura is empyema. This is much less common than tubercu-
lous pleurisy with effusion and results from a large number of
organisms spilling into the pleural space, usually from rupture
of a cavity or an adjacent parenchymal focus via a bronchop-
leural fistula (58). A tuberculous empyema is usually associ-
ated with evident pulmonary parenchymal disease on chest
films and air may be seen in the pleural space. In the absence
of concurrent pulmonary tuberculosis, diagnosis of pleural tu-




. In patients with genitourinary
tuberculosis, local symptoms predominate and systemic symp-
toms are less common (59, 60). Dysuria, hematuria, and fre-
quent urination are common, and flank pain may also be
noted. However, the symptoms may be subtle, and, often,
there is advanced destruction of the kidneys by the time a di-
agnosis is established (61). In women genital involvement is
more common without renal tuberculosis than in men and
may cause pelvic pain, menstrual irregularities, and infertility
as presenting complaints (60). In men a painless or only
slightly painful scrotal mass is probably the most common pre-
senting symptom of genital involvement, but symptoms of
prostatitis, orchitis, or epididymitis may also occur (59). A
substantial number of patients with any form of genitourinary
tuberculosis are asymptomatic and are detected because of an
evaluation for an abnormal routine urinalysis. In patients with
renal or genital tuberculosis, urinalyses are abnormal in more
than 90%, the main finding being pyuria, and/or hematuria.
The finding of pyuria in an acid urine with no routine bacterial
organisms isolated from a urine culture should prompt an
evaluation for tuberculosis by culturing the urine for myco-
bacteria. Acid-fast bacillus (AFB) smears of the urine should
be done, but the yield is low. The suspicion of genitourinary
tuberculosis should be heightened by the presence of abnor-
malities on the chest film. In most series, approximately 40 to
75% of patients with genitourinary tuberculosis have chest ra-
diographic abnormalities, although in many these may be the




. The usual presenting symptom of
skeletal tuberculosis is pain (62). Swelling of the involved joint
may be noted, as may limitation of motion and, occasionally,
sinus tracts. Systemic symptoms of infection are not common.
Since the epiphyseal region of bones is highly vascularized in
infants and young children, bone involvement with tuberculo-
sis is much more common in children than adults. Approxi-
mately 1% of young children with tuberculosis disease will de-
velop a bony focus (63). Because of the subtle nature of the
symptoms, diagnostic evaluations often are not undertaken
until the process is advanced. Delay in diagnosis can be espe-
cially catastrophic in vertebral tuberculosis, where compres-
sion of the spinal cord may cause severe and irreversible neu-
rologic sequelae, including paraplegia.
Fortunately, such neurologic sequelae represent the more se-
vere end of the spectrum. Early in the process the only abnor-
mality noted may be soft tissue swelling. Subsequently, subchon-
dral osteoporosis, cystic changes, and sclerosis may be noted
before the joint space is actually narrowed. The early changes of
spinal tuberculosis may be particularly difficult to detect by stan-
dard films of the spine. Computed tomographic scans and mag-
netic resonance imaging of the spine are considerably more sen-
sitive than routine films and should be obtained when there is a
high index of suspicion of tuberculosis. Bone biopsy may be
needed to obtain diagnostic material if the chest radiograph is
normal and the sputum smear and culture are negative.
 
Central nervous system tuberculosis
 
. Tuberculous meningitis
is a particularly devastating disease. Meningitis can result from
direct meningeal seeding and proliferation during a tubercu-
lous bacillemia either at the time of initial infection or at the
time of breakdown of an old pulmonary focus, or can result
from breakdown of an old parameningeal focus with rupture
into the subarachnoid space. The consequences of subarach-
noid space contamination can be diffuse meningitis or localized
arteritis. In tuberculous meningitis the process is located pri-
marily at the base of the brain (64). Symptoms, therefore, in-
clude those related to cranial nerve involvement as well as
headache, decreased level of consciousness, and neck stiffness.
The duration of illness before diagnosis is quite variable and
relates in part to the presence or absence of other sites of in-
volvement. In most series more than 50% of patients with men-
ingitis have abnormalities on chest film, consistent with an old
or current tuberculous process, often miliary tuberculosis.
Physical findings and screening laboratory studies are not
particularly helpful in establishing a diagnosis. In the presence
of meningeal signs on physical examination, lumbar puncture
is usually the next step in the diagnostic sequence. If there are
focal findings on physical examination or if there are sugges-
tions of increased intracranial pressure, a computerized tomo-
graphic scan of the head, if it can be obtained expeditiously,
should be performed before the lumbar puncture. With men-
ingitis, the scan may be normal but can also show diffuse
edema or obstructive hydrocephalus. Tuberculomas are gen-
erally seen as ring-enhancing mass lesions.
The other major central nervous system form of tuberculo-
sis, the tuberculoma, presents a more subtle clinical picture
than tuberculous meningitis (65). The usual presentation is
that of a slowly growing focal lesion, although a few patients
have increased intracranial pressure and no focal findings. The
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cerebrospinal fluid is usually normal, and the diagnosis is es-
tablished by computed tomographic or magnetic resonance





. Tuberculosis can involve any in-
traabdominal organ as well as the peritoneum, and the clinical
manifestations depend on the areas of involvement. In the gut
itself tuberculosis may occur in any location from the mouth to
the anus, although lesions proximal to the terminal ileum are
unusual. The most common sites of involvement are the termi-
nal ileum and cecum, with other portions of the colon and the
rectum involved less frequently (66). In the terminal ileum or
cecum the most common manifestations are pain, which may
be misdiagnosed as appendicitis, and intestinal obstruction. A
palpable mass may be noted that, together with the appearance
of the abnormality on barium enema or small bowel films, can
easily be mistaken for a carcinoma. Rectal lesions usually
present as anal fissures, fistulae, or perirectal abscesses. Be-
cause of the concern with carcinoma, the diagnosis often is
made at surgery. However, laparoscopy or colonoscopy with
biopsy may be sufficient to obtain diagnostic material.
Tuberculous peritonitis frequently causes pain as its pre-
senting manifestation, often accompanied by abdominal swell-
ing (66–69). Fever, weight loss, and anorexia are also common.
Active pulmonary tuberculosis is uncommon in patients with
tuberculous peritonitis. Because the process frequently coex-
ists with other disorders, especially hepatic cirrhosis with as-
cites, the symptoms of tuberculosis may be obscured. The
combination of fever and abdominal tenderness in a person
with ascites should always prompt an evaluation for intraab-
dominal infection, and a paracentesis should be performed.
However, this is often not diagnostic, and laparoscopy with bi-




. The symptoms, physical findings,
and laboratory abnormalities associated with tuberculous peri-
carditis may be the result of either the infectious process itself or
the pericardial inflammation causing pain, effusion, and eventu-
ally hemodynamic effects. The systemic symptoms produced by
the infection are quite nonspecific. Fever, weight loss, and night
sweats are common in reported series (70–72). Symptoms of car-
diopulmonary origin tend to occur later and include cough, dys-
pnea, orthopnea, ankle swelling, and chest pain. The chest pain
may occasionally mimic angina but usually is described as being
dull, aching, and often affected by position and by inspiration.
Apart from fever, the most common physical findings are
those caused by the pericardial fluid or fibrosis–cardiac tampon-
ade or constriction. Varying proportions of patients in reported
series have signs of full-blown cardiac constriction when first
evaluated. It is assumed that in these patients the acute phase of
the process was unnoticed. In the absence of concurrent extracar-
diac tuberculosis, diagnosis of pericardial tuberculosis requires




The contribution of the microbiology laboratory to the diag-
nosis and management of tuberculosis involves the detection
and isolation of mycobacteria, the identification of the myco-
bacterial species or complex isolated, and the determination
of susceptibilities of the organisms to antimycobacterial drugs.
Only laboratories having a sufficient volume of work and as-
sured competence should provide clinical mycobacteriology
services. Such procedures are time-consuming and employ re-
agents and special techniques not used routinely in the study
of bacteria in other genera. Furthermore, handling of myco-
bacterial specimens requires special safety precautions and
suitable isolation areas that may place a burden on some labo-
ratories.
 
A. Laboratory Services for Mycobacterial Diseases
 
With the closing of most tuberculosis sanatoria in the 1970s,
treatment of patients with tuberculosis moved to general hos-
pitals and outpatient clinics. The supporting mycobacteriology
services were spread diffusely through more and more labora-
tories, each processing fewer and fewer specimens. Recently,
managed care plans that centralize laboratory processing have
increased the number of specimens that are sent to regional
reference laboratories for processing, further decreasing the
numbers of mycobacteriology specimens processed locally.
Maintenance of laboratory proficiency requires continuing
and frequent performance of the required tests. When tests
are performed so infrequently that it is impractical to maintain
the materials and expertise required for proficiency, a decision
must be made concerning referral to another laboratory for
testing. In addition, because tuberculosis can be transmitted to
laboratory personnel who handle clinical specimens, adequate
training in proper techniques and the availability of special
containment areas are required for the safe manipulation of
clinical specimens. Protection of laboratory personnel and en-
vironment can be achieved by observing standard laboratory
practices and techniques, using appropriate safety equipment
properly, and designing a safe laboratory layout that includes
proper air handling (73, 74).
The laboratory and the clinicians requesting service must be
confident of the results the laboratory provides. However, be-
cause of patients with multidrug-resistant tuberculosis and in-
creased numbers of immunodeficient patients, results from di-
agnostic studies must also be timely. Waiting for well-grown
subcultures of mycobacteria to send to reference laboratories
may cause significant delays. Laboratories should use efficient
procedures, refer specimens to specialized laboratories as early
as possible, and ideally be staffed 7 d/wk to provide the most
rapid results possible. A laboratory may choose to develop or
maintain the skills for only some of the procedures required,
depending on the frequency with which specimens are received
for isolation of mycobacteria, the nature of the clinical commu-
nity being served, and the availability of a specialized referral
service. All laboratories doing clinical mycobacteriology must
participate in recognized proficiency testing programs (Clinical
Laboratory Improvement Amendments [CLIA 42 CFR-493]),
and levels of service should be established and limited by the
quality of performance demonstrated in these examinations.
Laboratories with a low volume of work should refer speci-
mens/cultures to laboratories that have chosen to maintain ca-
pabilities in mycobacteriology. This will save the time, effort,
and expense of setting up and maintaining quality control stan-
dards for tests that are performed only rarely. The full spec-
trum of bacteriologic support should be concentrated in the
laboratories in a given community or region where profes-
sional expertise and complete and safe facilities are available.
Physicians and laboratories must cooperate to achieve the
highest quality clinical mycobacteriology service (75).
 
B. Collection of Specimens for Demonstration
of Tubercle Bacilli
 
Because the identification of organisms is so critical in diag-
nosing tuberculosis, it is of utmost importance that careful at-
tention be given to the collection and handling of specimens.
Success in isolating mycobacteria from clinical materials de-
pends on the manner in which specimens are handled after
collection. For optimal results, specimens should be collected
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hibit growth of contaminating organisms, since most speci-
mens will contain bacteria other than mycobacteria.
Because mycobacterial disease may occur in almost any site
in the body, a variety of clinical materials may be submitted
to the laboratory for examination. In addition to the com-
mon specimens, such as sputum (natural or induced) and gas-
tric aspirate, others include urine, cerebrospinal fluid, pleural
fluid, bronchial washings, material from abscesses, endome-
trial scrapings, bone marrow, and other biopsy specimens or
resected tissue. The methods for collecting specimens are
briefly outlined below. All specimen collection procedures




(e.g., sputum, bronchoalveolar lavage, etc.) should be per-
formed in properly ventilated areas or safety cabinets by per-
sonnel using adequate respiratory protection (76, 77). If the





. Patients need to be instructed as to the proper
method of sputum collection. It is important that the patient
be informed that nasopharyngeal discharge and saliva are not
sputum; rather, the material brought up from the lungs after a
productive cough constitutes the material desired. Whenever
possible, attending personnel should observe the sputum col-
lection. A series of at least three single specimens (but usually
not more than six) should be collected initially (preferably on
different days) from sputum-producing patients. For optimal
results, sputum should be collected and processed in the same
container. Commercially available sputum collection devices
using a 50-ml plastic, single-use, disposable centrifuge tube is
recommended (78). Alternatively, a sterile, wide-mouth speci-
men container with a tightly fitting screwtop lid is adequate.
Specimens should be clearly labeled with patient-identifying
information and the date of collection. Every effort should be
made to prevent the exterior of the container from becom-
ing contaminated during the collection. The container should
be placed in a disposable watertight plastic bag before being




. For patients who have difficulty produc-
ing sputum, there are several methods of obtaining a speci-
men. Inhalation of an aerosol of sterile hypertonic saline (3–
15%), usually produced by an ultrasonic nebulizer, can be
used to stimulate the production of sputum (79). Even though
aerosol-induced specimens may appear thin and watery, they
should be processed. The specimen should be clearly labeled
as “induced sputum”so it will not be discarded by the labora-
tory as an inadequate specimen. Because the cough induced
by this method may be violent and uncontrolled, patients
should be in areas with adequate environmental controls such
as a hood or booth fitted with a high-efficiency particulate air
(HEPA) filter to prevent transmission. They should be at-





. Gastric aspiration may be necessary for
those patients, particularly children, who cannot produce spu-
tum even with aerosol inhalation. About 50 ml of gastric con-
tents should be aspirated early in the morning, after the pa-
tient has fasted for at least 8 to 10 h, and preferably while the
patient is still in bed. Gastric aspirates should be neutralized
immediately on collection. For these reasons, gastric aspira-
tion is best performed with hospitalized patients, according to





recovered from gastric aspirates in about 40% of those with
radiographic evidence of significant pulmonary disease (81, 82).
 
Bronchial washings, bronchoalveolar lavage, transbronchial
biopsy
 
. For patients in whom a diagnosis of tuberculosis has
not been established from sputum, fiberoptic bronchoscopy
performed with appropriate infection control precautions may
be needed with bronchoalveolar lavage, and/or transbronchial
biopsy (83). Even in the presence of significant pulmonary dis-
ease, the smears of bronchoalveolar lavage fluid may be nega-
tive. The topical agents used to anesthetize the airway mucosa




, so these agents should be
used judiciously. Patients should be placed in a room with ap-
propriate infection controls during and after the procedure.
Patient’s sputum produced after bronchoscopy (during the re-
covery phase and the next morning) should also be collected
and examined. The procedure may cause the patient to con-
tinue producing sputum for several days. These later speci-
mens should also be collected and examined. Physical cleaning
of the bronchoscope followed by chemical sterilization is abso-
lutely essential since documented transmission through a con-




. The first morning-voided midstream specimen is
preferred. Multiple specimens are advised to demonstrate the
presence of mycobacteria. Smears of urine are usually nega-
tive and therefore may not be cost-effective to perform. It is
preferable that the patient not be receiving broad-spectrum
antibiotics at the time of collection because the antibiotics




. Blood for mycobacterial culture should be anticoagu-
lated with heparin and processed with a commercially available
lysis centrifugation system or inoculated into commercially avail-
able broth media designed for mycobacterial blood cultures.
Blood collected in ethylenediaminetetraacetic acid (EDTA/pur-




. Cerebrospinal fluid should be analyzed
for protein and glucose (compared with simultaneous serum
total protein and glucose). Total white blood cell and differen-





the serum protein concentration), lymphocytosis, and low glu-
cose are typical of tuberculous meningitis. A minimum of 5 ml
should be submitted to the laboratory in a sterile container for
mycobacterial culture. The AFB smear of cerebrospinal fluid
is usually negative; however, the culture may be positive. If
the laboratory concentrates the fluid before smear and cul-




10 ml) can lead to increased yield,
but may also increase complications of the procedure.
 
Tissue and other body fluids
 
. Under a variety of circum-
stances, when noninvasive techniques have not provided a di-
agnosis, tissue or other body fluids should be obtained for his-
tologic evaluation and culture (for both mycobacteria and
fungi). Expeditious and appropriate handling of the specimen
must be assured before the physician performs an invasive
procedure to obtain the specimen. Especially important is
rapid transportation to the laboratory in an appropriate con-
tainer, either without preservative, or in the correct medium
for the culture, according to the laboratory’s instructions. The
portion of the specimen put in formalin for histologic exami-
nation cannot be used for culture.
Pleural, peritoneal, and pericardial fluids may be analyzed
for protein and glucose (compared with simultaneous serum
total protein and glucose). Cell and differential counts should




50% of the serum protein con-
centration), lymphocytosis, and a low glucose are usually
found in tuberculous infections, but neither their presence nor
their absence is diagnostic. Adenosine deaminase (ADA), a
purine-degrading enzyme that is necessary for the maturation
and differentiation of lymphoid cells, has been reported in a
number of studies to be elevated in these fluids when tubercu-
losis involves these sites (87, 88). However, the utility of the
routine measurement of ADA has not been determined and
this test is not generally available. The numbers of organisms
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in the pleural fluid from most cases of tuberculous pleuritis is
relatively low, with positive cultures found in less than 25% of
cases. Pleural biopsy shows granulomatous inflammation in
approximately 60% of patients. However, when culture of
three biopsy specimens is combined with microscopic exami-
nation, the diagnosis can be made in up to 90% of cases (89).
Pleuroscopy-guided biopsies increase the yield in pleural sam-
pling. Peritoneal biopsies are best obtained via laparoscopy.
Tissue biopsy. Invasive procedures to obtain specimens
from the lung, pericardium, lymph nodes, bones and joints,
bowel, salpinges, and epididymis should be considered when
noninvasive techniques do not provide a diagnosis. Many of
these areas are amenable to closed techniques such as percuta-
neous needle biopsy or aspiration, transbronchial biopsy, or
brushing, precluding a need for formal surgical procedures. In
patients with hematogenous or disseminated disease, bone
marrow biopsy, lung biopsy, and liver biopsy for histologic ex-
amination and culture should be considered. Appropriate
measures must be taken when collecting these specimens to
minimize aerosolation of M. tuberculosis organisms and pre-
vent transmission of infection to personnel.
C. Transport of Specimens to the Laboratory
Clinical specimens, which must be labeled clearly and accu-
rately, should be transported or mailed to the laboratory and
processed as soon as possible after collection. To minimize tran-
sit time, the use of overnight delivery should be considered. If a
delay is anticipated, the specimen should be refrigerated until
prompt delivery can be assured. The Interstate Shipment of Eti-
ologic Agents (42 CFR, Part 72) provides specific instructions
for packing and labeling of infectious agents. Authorized pack-
aging and components include the following: (1) an inner pack-
age that contains a watertight primary receptacle, watertight
secondary packaging, and absorbent material between the pri-
mary and secondary receptacle; and (2) outer packaging that is
of adequate strength for its capacity, mass, and intended use.
Clear labeling of packages specifying the contents is necessary.
Standardized biohazard labels for this purpose are available.
Additional information can be obtained from the Centers for
Disease Control and Prevention, Office of Health and Safety
(1600 Clifton Road, Atlanta, GA 30333; website: www.cdc.gov/
od/ohs/). If the specimen cannot be shipped promptly to the lab-
oratory, it should be refrigerated until shipped. No fixative or
preservation agents should be used.
D. Digestion and Decontamination of Specimens
Most clinical specimens contain an abundance of nonmyco-
bacterial organisms. Unless an attempt is made to inhibit these
usually fast-growing contaminants, they can quickly overgrow
the generally more slowly reproducing (18- to 24-h generation
time in culture) mycobacteria on the culture medium. It is also
necessary to liquefy the organic debris (tissue, serum, and
other proteinaceous material) surrounding the organisms in
the specimen so that decontaminating agents may kill undesir-
able microbes, and surviving mycobacteria may gain access to
the nutrients of the medium onto which they are subsequently
inoculated. Because mycobacteria are more refractory to
harsh chemicals than are most other microorganisms, chemi-
cal decontamination procedures have been successfully ap-
plied to ensure the recovery of acid-fast bacteria from clinical
materials.
On arrival in the laboratory, most specimens are homoge-
nized with a mucolytic agent (such as N-acetyl-L-cysteine) and
decontaminant (such as a 1–2% sodium hydroxide solution) to
render the bacterial contaminants nonviable. The mildest de-
contamination procedure that provides sufficient control of the
contaminants without killing the mycobacteria is likely to yield
the best results (78). However, even under optimal conditions,
these procedures kill all but 10 to 20% of the mycobacteria in
the specimen (90, 91). As a general rule for Löwenstein–Jensen
medium, there should be approximately 2–5% of sputum spec-
imens that are contaminated. If fewer than 2% of specimens
are contaminated, the process may be killing many of the my-
cobacteria as well as contaminants. If more than 5% of the cul-
tures are contaminated, the decontamination process is inade-
quate (92). Tissues may be ground in homogenizers and
decontaminated. Specimens collected from normally sterile
sites may be placed directly into the culture medium.
E. Staining and Microscopic Examination
The detection of acid-fast bacilli (AFB) in stained smears ex-
amined microscopically is the first bacteriologic evidence of
the presence of mycobacteria in a clinical specimen. It is the
easiest and quickest procedure that can be performed, and it
provides the physician with a preliminary confirmation of the
diagnosis. Also, because it gives a quantitative estimation of
the number of bacilli being excreted, the smear is of vital clini-
cal and epidemiologic importance in assessing the patient’s in-
fectiousness.
Smears may be prepared directly from clinical specimens or
from concentrated preparations. The acid-fast staining proce-
dure depends on the ability of mycobacteria to retain dye
when treated with mineral acid or an acid–alcohol solution.
Two procedures are commonly used for acid–fast staining: the
carbolfuchsin methods, which include the Ziehl–Neelsen and
Kinyoun methods, and a fluorochrome procedure using au-
ramine-O or auramine–rhodamine dyes. Several quantitative
studies have shown that there must be 5,000 to 10,000 bacilli
per milliliter of specimen to allow the detection of bacteria in
stained smears (93). In contrast, 10 to 100 organisms are needed
for a positive culture (94). Concentration procedures in which
a liquefied specimen is centrifuged and the sediment is used
for staining increases the sensitivity of the test; thus, smears of
concentrated material are preferred. Negative smears, how-
ever, do not preclude tuberculosis disease. Various studies
have indicated that 50 to 80% of patients with pulmonary tu-
berculosis will have positive sputum smears. Factors influenc-
ing the sensitivity of smears include staining technique, cen-
trifugation speed, reader experience, and the prevalence of
tuberculosis disease in the population being tested.
In reading smears, the microscopist should provide the cli-
nician with a rough estimate of the number of AFB detected.
Table 2 shows a frequently used scheme to quantify organisms
seen on AFB smear.
Acid-fast bacteria seen on smear may represent either M.
tuberculosis or nontuberculous mycobacteria. However, be-
cause of the infectious potential of M. tuberculosis, acid-fast
TABLE 2
QUANTITATION SCALE FOR ACID-FAST BACILLUS




(3 250) Quantity Reported
No AFB/300 fields No AFB/30 fields No AFB seen
1–2 AFB/300 fields 1–2 AFB/30 fields Doubtful, repeat test
1–9 AFB/100 fields 1–9 AFB/10 fields Rare (11)
1–9 AFB/10 fields 1–9 AFB/field Few (21)
1–9 AFB/field 10–90 AFB/field Moderate (31)
. 9 AFB/field . 90 AFB/field Numerous (41)
1384 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 161 2000
stains should be performed within 24 h of receipt in the labo-
ratory and results should be reported to the physician immedi-
ately (95). Hospitalized patients should be placed in respira-
tory isolation until the absence of M. tuberculosis is definitely
known or the patient has been treated with medications and is
no longer thought to be infectious. There is no need to hospi-
talize a person solely because they are infectious. Outpatients
should be instructed to remain at home, without visitors, until
they are no longer thought to be infectious. Also, individuals
who are particularly susceptible to developing tuberculosis
disease if they become infected (small children, immunocom-
promised individuals) should not visit or live with the patient
while they can transmit infection.
The percentage of specimens shown positive by smear but
negative in culture should be less than 1% (96). Most smear-
positive, culture-negative specimens are seen in patients who
are taking antimycobacterial therapy. Laboratory errors, pro-
longed specimen decontamination, shortened incubation times
of culture, cross-contamination of smears, and water or stains
contaminated with acid-fast organisms can result in smear-
positive, culture-negative specimens (78).
F. Identification of Mycobacteria Directly from
Clinical Specimens
A dramatic improvement in the direct detection and identifi-
cation of M. tuberculosis has resulted from methods using nu-
cleic acid amplification techniques. These technologies allow
for the amplification of specific target sequences of nucleic ac-
ids that can then be detected through the use of a nucleic acid
probe. Both RNA and DNA amplification systems (97, 98) are
commercially available. The uses of nucleic acid amplification
for the diagnosis of tuberculosis are rapidly evolving and the
discussion below represents a cautious view that should be
modified as additional information becomes available.
Nucleic acid amplification methods can be applied to clini-
cal specimens within hours. In the research laboratory, these
procedures can produce a positive result from specimens con-
taining as few as 10 bacilli (79); however, in clinical laborato-
ries, the sensitivity is somewhat less. When evaluating the util-
ity of these tests, it is important to keep in mind that initial
studies were performed from the perspective of the labora-
tory, not from the clinical perspective. In clinical respiratory
specimens that are AFB smear positive, the sensitivity of the
amplification methods is approximately 95%, with a specific-
ity of 98%. In specimens that contain fewer organisms and are
AFB smear negative, the nucleic acid amplification test is pos-
itive in 48–53% of patients with culture-positive tuberculosis
and the specificity remains approximately 95% (99). Thus, the
CDC included a positive nucleic acid amplification test in the
setting of a positive smear as confirmation of the diagnosis of
tuberculosis (100). An “enhanced” nucleic acid amplification
test has been approved by a Food and Drug Administration
(FDA) advisory panel for use on both smear-positive and
smear-negative respiratory specimens from patients who are
clinically suspected of having tuberculosis. This recommenda-
tion was based on a clinical trial in which the “suspicion” of tu-
berculosis disease was quantified (101). In patients (AFB
smear positive and negative) where the clinician had an inter-
mediate or high suspicion of tuberculosis disease, the sensitiv-
ity of the enhanced nucleic acid amplification test was 75–88%
and the specificity was 100%. The clinical use of nucleic acid
amplification in this setting needs to be confirmed and efforts
to clarify appropriate uses are underway (100, 102). On the ba-
sis of available information, decisions about when and how to
use nucleic amplification tests should be individualized. These
tests may enhance diagnostic certainty, particularly in patients
where prompt treatment is imperative (e.g., immunocompro-
mised) (103), but should be interpreted in a clinical context
and on the basis of local laboratory performance (100). Newer
methods for nucleic acid amplification are being developed to
increase the sensitivity and specificity of the test.
Nucleic acid amplification methods do not replace the need
for routine AFB smear and culture, especially when drug sus-
ceptibility tests are to be performed. However, these tests can
greatly increase confidence in the clinical diagnosis pending
culture results. As with other laboratory techniques, results
from nucleic acid amplification methods must be interpreted
in the context of the patient’s signs and symptoms, and the
prevalence of tuberculosis within the community. Laboratory
contamination, and technician and sampling errors, can cause
false-positive results. Also, nucleic acid amplification proce-
dures can detect nucleic acids from dead as well as live M. tu-
berculosis and, therefore, can remain positive for long periods
in patients who have completed tuberculosis therapy. Thus,
this method should be used only for initial diagnosis and not
follow-up evaluations of patients who are receiving antimyco-
bacterial drugs.
G. Cultivation of Mycobacteria
All clinical specimens suspected of containing mycobacteria
should be inoculated (after appropriate digestion and decon-
tamination, if required) onto culture media for four reasons:
(1) culture is much more sensitive than microscopy, being able
to detect as few as 10 bacteria/ml of material (94); (2) growth
of the organisms is necessary for precise species identification;
(3) drug susceptibility testing requires culture of the organ-
isms; and (4) genotyping of cultured organisms may be useful
to identify epidemiological links between patients or to de-
tect laboratory cross-contamination. In general, the sensitivity
of culture is 80–85% with a specificity of approximately 98%
(104, 105).
Although the diagnosis of tuberculosis disease is mainly
bacteriologic in adults, it is usually epidemiologic and, thus, in-
direct in children (106). For example, from 1985 to 1988 in the
United States, 90% of tuberculosis cases in adults were bacte-
riologically confirmed, compared with 28% in children (107).
In HIV-infected pediatric tuberculosis cases, the bacteriologic
confirmation of disease appears to be much higher, possibly
because of the dissemination of the organism or higher bacte-
rial burdens.
Three different types of traditional culture media are avail-
able: egg based (Löwenstein–Jensen), agar based (Middle-
brook 7H10 or 7H11 medium), and liquid (Middlebrook 7H12
and other commercially available broths), and each can be
made into selective media by adding antibiotics. Of the solid
media, growth of mycobacteria tends to be slightly better on
the egg-based medium but more rapid on the agar medium.
Growth in liquid media is faster than growth on solid media.
However, liquid media can be used for primary isolation of
mycobacteria from nonsterile sites only if supplemented with
an antibiotic cocktail.
A major improvement in mycobacteriology has been the
development of commercial broth systems for mycobacterial
growth detection. Automated culture systems such as BACTEC
460 (Becton Dickinson Microbiology Systems, Sparks, MD),
mycobacterial growth indicator tube (MGIT) systems, ESP
(Extra Sensing Power) Myco-ESPculture System II (Trek Di-
agnostic Systems, Inc., Westlake, OH), and BacT/ALERT MB
Susceptibility Kit (Organon Teknika, Durham, NC) use Mid-
dlebrook 7H12 media with added material for detection of
mycobacteria (radiometric or colorimetric systems). Liquid
systems allow for rapid growth [detection of mycobacterial
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growth within 1–3 wk compared with solid media, where
growth takes 3–8 wk (104)], whereas agar media provide an
opportunity to examine colony morphology and detect mixed
cultures. At least one container of solid medium should be in-
oculated and used in conjunction with broth culture systems.
Egg-based media such as Löwenstein–Jensen slants are an im-
portant backup for rare M. tuberculosis strains that may not
grow on the other media. Automated liquid systems should be
checked at least every 2–3 d for growth while solid media
should be checked once or twice a week.
Mycobacterial growth observed on solid culture media
should be quantified. Growth in liquid culture systems cannot
be similarly quantitated although a qualitative measure of or-
ganisms in the inoculum can be made by noting the time re-
quired for liquid culture to turn positive. Table 3 presents a
widely used scale for quantitating growth on agar plates.
H. Identification of Mycobacteria from Culture
The genus Mycobacterium consists of more than 80 different
species of organisms, all of which appear similar on acid-fast
staining. More than half of them, both saprophytes and poten-
tial pathogens, may be isolated from humans. The specialized
laboratory, through the use of a variety of in vitro tests, should
be able to provide a precise species identification of most acid-
fast bacilli isolated from patients. A clear-cut distinction be-
tween pathogen and saprophyte is not always possible for the
individual isolate. Isolation of a nontuberculous organism of
potential clinical significance is not ipso facto evidence that
the patient has disease caused by the organism; conversely, all
such isolates, which are usually clinically insignificant, should
not be regarded as saprophytes. Each mycobacterial isolate,
like each patient, must be evaluated individually (108).
Historically, M. tuberculosis could readily be identified by
its rough, nonpigmented, corded colonies on oleic acid–albu-
min agars; a positive niacin test; generally weak catalase activ-
ity, that is lost completely by heating to 688 C; and a positive
nitrate reduction test. Observation of mycobacterial colonial
morphology remains a valuable tool. Although the colonial
morphologies of mycobacteria on various egg-based media
may be quite similar, their appearance on Middlebrook 7H10
or 7H11 agar is distinctive (109).
Biochemical methods can distinguish mycobacterial spe-
cies, but are time-consuming and laborious. Two identification
procedures that are based on distinctive molecular character-
istics of M. tuberculosis have gained widespread use: nucleic
acid hybridization and high performance liquid chromatog-
raphy (HPLC). Nucleic acid hybridization uses molecular
probes that can hybridize specifically with M. tuberculosis
complex, M. avium complex, M. kansasii, and M. gordonae
(79). Nucleic acid probes for other specific mycobacterial spe-
cies are not yet commercially available. These assays can be
completed within hours and have sensitivities and specificities
approaching 100% when at least 105 organisms are present.
This requirement is easily met when pure cultures are used but
is rarely achieved with clinical specimens. Thus nucleic acid
hybridization is typically used after the organisms are grown in
culture.
HPLC is based on the observation that each Mycobacte-
rium species synthesizes a unique set of mycolic acids, b-hy-
droxy-a-fatty acids that are components of the cell wall (110).
HPLC can produce a pattern that reliably identifies and distin-
guishes . 50 mycobacterial species. It can be performed in a
few hours but requires organisms from pure cultures. HPLC is
particularly useful since it can replace an entire battery of bio-
chemical tests. However, it cannot differentiate M. tuberculo-
sis from M. bovis, although it can differentiate M. bovis BCG
from M. tuberculosis complex. The initial equipment cost for
HPLC limits its availability. Newer molecular techniques for
species identification, such as spoligotyping, polymerase chain
reaction restriction analysis (PRA), and DNA sequencing, are
on the horizon.
I. Drug Susceptibility Testing
Drug susceptibility tests should be performed on initial iso-
lates from all patients in order to identify what should be an
effective antituberculous regimen. In addition, drug suscepti-
bility tests should be repeated if the patient continues to pro-
duce culture-positive sputum after 3 mo of treatment or devel-
ops positive cultures after a period of negative cultures. There
are four conventional laboratory methods for detecting myco-
bacterial resistance: (1) the agar proportion method, (2) the
liquid radiometric method, (3) the absolute concentration
method, and (4) the resistance ratio method (91). The absolute
concentration methodology and the resistance ratio method
(111) are not used in the United States.
Direct and indirect methods. The source of the inoculum for
a susceptibility test may be either a smear-positive specimen
(direct method) or growth from a primary culture or subcul-
ture (indirect method). The direct method can be used only
when large numbers of organisms are seen on stained smears.
The indirect method is considered the standard method for in-
oculum preparation and results of the direct method are usu-
ally confirmed by subsequent testing using the indirect method.
With both the direct and indirect methods, careful attention
must be given to avoid over- or underinoculation. For the di-
rect method, the inoculum is either a digested, decontami-
nated clinical specimen, or an untreated normally sterile body
fluid. To ensure adequate but not excessive growth in the di-
rect susceptibility test on solid medium, specimens are diluted
according to the number of organisms observed in the stained
smear of the clinical specimen. Theoretically, this type of inoc-
ulum is more representative of the population of the tubercle
bacilli in a particular lesion in the host. If the smear-positive
specimen is from a patient who is receiving antimicrobial ther-
apy, it is prudent to include an undiluted inoculum because a
significant proportion of the bacilli seen on the smear may be
nonviable.
Use of the direct method may be warranted when there is a
high prevalence of drug resistance, especially when second-
line drugs are included in the initial test panel. Because direct
susceptibility testing is done immediately on receipt of the
specimen and does not require prior growth of organisms, the
time required to identify susceptibility patterns may be re-
duced. However, cost can be a critical factor when there is a
high incidence of smear-positive specimens containing nontu-
berculous mycobacteria. The direct method is not recom-
mended for routine use with liquid medium methods at this
time, since this application has had only limited evaluation.
For the indirect method the source of the inoculum is a
TABLE 3
QUANTITATION SCALE FOR MYCOBACTERIAL
GROWTH ON AGAR PLATES
No. of Colonies Seen Quantity Reported
No colonies seen Negative
Fewer than 50 colonies Report actual number seen
50–100 colonies 11
100–200 colonies 21
200–500 colonies (almost confluence) 31
. 500 colonies (confluence) 41
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subculture usually from the primary isolation medium. Care-
ful attention should be given to the selection of colony types
so that the final inoculum is representative of all types present,
to ensure that there is a balance of potentially resistant and
susceptible bacilli. The source of inoculum for the BACTEC
method can be growth on Middlebrook 7H10 or 7H11 agar or
on an egg-based medium. Turbid growth in a liquid medium
or sufficient growth in BACTEC 12B medium is also accept-
able; however, one should remember that a mixed culture (M.
tuberculosis and nontuberculous mycobacteria) can result in
apparent resistance, especially when the inoculum is derived
from a broth culture. Smear and subculture of BACTEC bot-
tles showing growth in the presence of drug is therefore rec-
ommended.
The agar and radiometric BACTEC proportion methods
are used by most laboratories in the United States that per-
form mycobacterial susceptibility testing. The agar proportion
method allows for the quantitation of the proportion of organ-
isms that is resistant to a given drug at a specified concentra-
tion. For a test to be valid, isolated, countable colonies (50 to
150) must be obtained on the drug-free medium. The number
of colonies observed on the drug-containing medium is then
compared with the number on the drug-free medium. The
proportion of bacilli that is resistant to a given drug can be de-
termined and expressed as a percentage of the total popula-
tion tested. This proportion has been set at 1%, because when
1% or more of the mycobacterial population is resistant to the
critical concentration of a drug, that agent is not, or soon will
not be, useful for therapy. The critical concentration of a drug
is the level of drug that inhibits the growth of most cells within
the population of a “wild” type strain of tubercle bacilli with-
out appreciably affecting the growth of the resistant mutant
cells that might be present. Wild strains are those that have
never come into contact with antituberculosis agents. These
strains have a similar degree of susceptibility and show a nar-
row range of minimal inhibitory concentrations (MICs) to an-
tituberculous drugs (112). The critical concentrations of the
drugs being tested should be included when drug susceptibility
test results are reported (91).
To generate rapid testing and faster turnaround time for
better patient management, the radiometric BACTEC 460 sys-
tem can be used to test all primary drugs (isoniazid, rifampin,
pyrazinamide, and ethambutol). The rapid availability of re-
sults using the BACTEC procedure may take precedence over
cost considerations. Many laboratories will follow up detec-
tion of resistance by the BACTEC method by testing the same
patient’s culture by the agar proportion method. The addi-
tional testing may include the equivalent critical concentra-
tions of primary drugs in agar proportion to confirm the
BACTEC results and higher concentrations of primary drugs
to determine the level of drug resistance. In comparing the re-
ported results between the two methods, clinicians should dif-
ferentiate which are the equivalent critical concentrations and
which are the higher concentrations of primary drugs (Table 4).
Testing of pyrazinamide using the BACTEC method is dif-
ferent from the BACTEC method used with the other primary
drugs because pyrazinamide activity must be measured at pH
5.5 rather than pH 6.8, the usual pH of the growth medium.
However, most strains of M. tuberculosis grow poorly at pH 5.5
and some fail to grow altogether. As a compromise between
testing at the pH for optimum pyrazinamide activity versus op-
timum growth, pH 6.0 has been chosen for testing pyrazina-
mide. In addition, to accurately and reliably test pyrazinamide
several other adjustments are made to the standard radiomet-
ric method (113). If an isolate tests resistant to pyrazinamide,
especially if the isolate is resistant to pyrazinamide alone, the
identity of the isolate should be confirmed since M. bovis and
M. bovis BCG are pyrazinamide resistant whereas the majority
of M. tuberculosis isolates are pyrazinamide susceptible. This is
especially important if the laboratory identifies isolates only to
the level of the M. tuberculosis complex.
Susceptibility test results should be reported without delay.
The report should include the method used, the name of the
drug, the concentration tested, and the result (susceptible or
resistant for the BACTEC method, susceptible or percent re-
sistant for the agar proportion method). Drug resistance
should be reported by telephone and/or facsimile to the re-
questing physician, infection control staff, and the local tuber-
culosis control program with a follow-up hard copy report. It
is prudent to confirm the receipt of a facsimile report by direct
communication with the physician or public health official.
Clinician concerns about discrepancies between susceptibil-
ity test results and clinical response or status must be communi-
cated back to the laboratory as part of an effective quality as-
surance program. Commonly, an M. tuberculosis isolate may
test by either the agar or BACTEC proportion method as re-
sistant to isoniazid, ethambutol, or streptomycin at the concen-
tration of the drug tested. Although the agar proportion and
BACTEC methods represent break-point susceptibility testing
with a single critical concentration of drug, some laboratories
test an additional, higher concentration of drug for isoniazid,
ethambutol, and streptomycin. The critical concentration of
TABLE 4
RECOMMENDED DRUG CONCENTRATIONS FOR DRUG PANEL SUSCEPTIBILITY TESTING*
Drug
Radiometric






Isoniazid 0.1‡ 0.2‡ 0.2‡ 0.1‡ 0.1 0.09
Isoniazid (high) 0.4 1.0 1.0 0.4 0.4 0.4
Rifampin 2.0‡ 1.0‡ 40.0‡ 1.0‡ 1.0 0.9
Ethambutol 2.5‡ 5.0‡ 2.0‡ 5.0‡ 5.0 2.3
Ethambutol (high) 7.5 10.0 8.0 — 7.5 —
Pyrazinamide 100‡ 25.0‡ — — 100 200
Streptomycin 2.0‡ 2.0‡ 4.0‡ — 1.0 0.9
Streptomycin (high) 6.0 10.0 — — 4.0 —
Definition of abbreviations: ESP Myco 5 ESP (Extra Sensing Power) Culture System II; MGIT 5 mycobacterial growth indicator tube; BacT/
ALERT MB 5 BacT/ALERT MB Susceptibility Kit.
* Micrograms per milliliter.
† MGIT and BacT/ALERT MB are not FDA approved.
‡ Critical concentration of the drug in this medium.
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drug determines whether the isolate is considered resistant.
The additional higher concentration of drugs, however, can
provide the physician with information about the level of drug
resistance in deciding whether to continue therapy with a drug
either at the recommended dose or at an increased dose. When
drug resistance is noted, it is important that the clinician with
less experience seek assistance from experts in the field or
from the local tuberculosis control program and the strain
should be retested and confirmed as to its resistance pattern.
Investigations into mechanisms of antimicrobial drug ac-
tion and of resistance in M. tuberculosis have benefited from
studies in other bacterial species, especially Escherichia coli
(114). A particular focus of such studies has been rifampin re-
sistance because of the pivotal role of rifampin in the treat-
ment of tuberculosis, the conserved nature of the genetic basis
for resistance (. 96% of rifampin resistance in M. tuberculosis
correlates with mutations in an 81-bp segment of the rpoB
gene), and the use of rifampin resistance as a marker of multi-
drug-resistant M. tuberculosis. The methods employed to de-
tect rpoB mutations include PCR amplification of the target
sequence and detection by DNA sequencing, line probe assay,
single-strand conformation polymorphism, and other molecu-
lar procedures. Before these techniques become widespread,
technical simplification or automation, as well as outcome
analysis in order to justify the anticipated increased costs com-
pared with conventional approaches, will be required.
J. Genotyping of Mycobacterium tuberculosis
Genotyping or DNA fingerprinting of M. tuberculosis has re-
placed phage typing as a method for determining the clonality
of bacterial cultures. The Southern blotting method is used,
whereby cultured organisms are heat killed and their DNA is
isolated, cut with specific restriction enzymes, separated in an
agarose gel by electrophoresis, transferred to a membrane,
and probed for specific genetic sequences. A standardized
protocol has been developed to permit comparison of geno-
types from different laboratories around the world (115).
Genotyping is useful in confirming laboratory cross-contami-
nation (116), investigating outbreaks of tuberculosis (117), eval-
uating contact investigations (118), and determining whether
new episodes of tuberculosis are due to reinfection or reacti-
vation (26). In addition, genotyping is useful for elucidating
sites and patterns of M. tuberculosis transmission within com-
munities (119, 120).
In response to several nosocomial outbreaks and a dra-
matic increase in tuberculosis among HIV-infected patients
in the early 1990s, the Centers for Disease Control and Pre-
vention established a National Tuberculosis Genotyping and
Surveillance Network. The merger of modern molecular pro-
tocols for strain identification at the DNA level and conven-
tional epidemiological methodologies has given birth to an en-
hanced collaborative strategy to impact tuberculosis control
efforts. Regional tuberculosis genotyping laboratories can be
contacted through the state public health laboratories or tu-
berculosis control programs.
K. Assessment of Laboratory Performance
There has been a growing body of new and exciting methods
in mycobacteriology, but there is still no single test that is di-
agnostic in all situations. Complementary techniques should
be used to generate complete and rapid information. The lab-
oratory director needs to decide which tests will be best per-
formed in-house, taking into consideration the need for rapid
results, particularly AFB smear results. Possible options for
small laboratories would include splitting a specimen, with
one portion processed locally for AFB smear and the other
portion sent for culture to a reference laboratory; or obtain-
ing two specimens, with one processed locally so that smear
results can be obtained within 24 h and the other specimen
shipped to a reference laboratory for further processing. Deci-
sions as to which specimens should be sent to a reference labo-
ratory should be based on the community served and the re-
sources available, as well as in consultation with infectious
disease, pulmonary, or other affected physicians. With this
partnership, physicians will then share the responsibility for
the quality and timeliness of laboratory results.
VI. TUBERCULIN SKIN TEST
The tuberculin skin test is currently the only widely used
method for identifying infection with M. tuberculosis in per-
sons who do not have tuberculosis disease. Although currently
the tuberculin skin test antigens that are available are substan-
tially less than 100% sensitive and specific for detection of in-
fection with M. tuberculosis, no better diagnostic method is
widely available. Proper use of the tuberculin skin test re-
quires a knowledge of the antigen used (tuberculin), the im-
munologic basis for the reaction to this antigen, the tech-
nique(s) of administering and reading the test, and the results
of epidemiologic and clinical experience with the test.
A. Tuberculin
The tuberculin test is based on the fact that infection with M.
tuberculosis produces a delayed-type hypersensitivity reaction
to certain antigenic components of the organism that are con-
tained in extracts of culture filtrates called “tuberculins.” Two
companies manufacture tuberculin purified protein derivative
(PPD) in the United States: Parke-Davis Pharmaceuticals
(Aplisol) and Pasteur Mérieux-Connaught Laboratories (Tu-
bersol). Tuberculin PPD is isolated from a culture filtrate of
tubercle bacilli by protein precipitation. The most commonly
employed methods of precipitation use either ammonium sul-
fate (AS) or trichloroacetic acid (TCA). Aplisol is isolated by
the AS method; Tubersol is isolated by the TCA method.
Standardization should guarantee equivalent potency be-
tween PPD preparations isolated by different precipitation
methods and between successive lots isolated by a single
method. However, the difference in the chemical composition
of the PPDs produced by the different precipitation methods
implies that the actual antigens in the two preparations do dif-
fer. Most of the constituents of PPD are small proteins with
molecular masses of approximately 10,000 Da, but there are
also polysaccharides and some lipids present (121). The rela-
tively small size of the protein constituents in PPD is the rea-
son that PPD does not sensitize individuals who have not been
exposed to mycobacteria (121).
A batch of PPD (lot 49608) called PPD-S, which was pro-
duced by Seibert and Glenn in 1939, has continued to serve as
the international standard as well as the standard reference
material in the United States (122). All PPD lots must be bio-
assayed to demonstrate equal potency to PPD-S (123). “Tu-
berculins” and “PPDs” have been prepared from other myco-
bacterial species, but these materials are less sensitive and
specific for diagnosis of nontuberculous mycobacterial infec-
tions than is PPD for M. tuberculosis infections. These prepara-
tions are occasionally used for epidemiologic purposes (124),
but have little clinical utility.
The standard 5-tuberculin unit (TU) dose of PPD-S is de-
fined as the delayed skin test activity contained in a PPD-S dose
of 0.1 mg/0.1 ml. The standard test dose of a commercial PPD
preparation is defined as the dose of the product that is biologi-
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cally equivalent to that contained in 5 TU of PPD-S (i.e., it elic-
its reactions of equivalent size 6 20%). Other doses of tubercu-
lin, such as 1 and 250 TU, are remnants of the old graduated
system of administration (125) and represent the smallest and
largest doses of tuberculin that were administered. These
strengths of tuberculin are not commonly available and, even if
available, are not standardized by bioassay. The clinical utility
of these concentrations of tuberculin is minimal.
PPD, when diluted in a buffered diluent, is adsorbed in
varying amounts by glass and plastics. A small amount of the
detergent Tween 80 is added by the manufacturer to the dilu-
ent for PPD to reduce adsorption (126). To minimize reduc-
tion in potency by adsorption, tuberculin should never be
transferred from one container to another, and skin tests
should be given as soon after the syringe has been filled as
possible. Following these procedures will also help avoid con-
tamination: test doses should always be removed from the vial
under strictly aseptic conditions, and the remaining solution
should be kept refrigerated (not frozen). Tuberculin should be
stored in the dark as much as possible and exposure to strong
light should be avoided.
B. Immunologic Basis for the Tuberculin Reaction
The reaction to intracutaneously injected tuberculin is the
classic example of a delayed (cellular) hypersensitivity reac-
tion. T cells sensitized by prior infection are recruited to the
skin site where they release lymphokines (127). These lym-
phokines induce induration through local vasodilatation,
edema, fibrin deposition, and recruitment of other inflamma-
tory cells to the area (128). Features of the reaction include (1)
its delayed course, reaching a peak more than 24 h after in-
jection of the antigen; (2) its indurated character; and (3) its
occasional vesiculation and necrosis. Reactivity of the PPD
provides a general measure of a person’s cellular immune re-
sponsiveness (121).
Typically, the reaction to tuberculin begins 5 to 6 h after in-
jection, causes maximal induration at 48 to 72 h, and subsides
over a period of days. In a few individuals (the elderly and
those who are being tested for the first time), the reaction may
not peak until after 72 h (129). Such delayed reactions do not
alter the intrepretation of the test. Immediate hypersensitivity
reactions to tuberculin or constituents of the diluent can also
occur. These reactions disappear by 24 h, and should not be
confused with delayed hypersensitivity reactions. However, if
the immediate reaction is severe, it may be prudent not to re-
test. Symptom screening is suggested if these individuals are
part of a regular tuberculin skin testing program (e.g., health-
care workers).
C. Administration and Reading of Tests
The tuberculin test, like all medical tests, is subject to variabil-
ity, but many of the inherent variations in administration and
reading of tests can be avoided by careful attention to details.
The test is administered by injecting 0.1 ml of 5-TU PPD intra-
dermally (Mantoux method) into the volar or dorsal surface of
the forearm. Other areas may be used, but the forearm is pre-
ferred. The use of a skin area free of lesions and away from
veins is recommended. The injection is made using a one-
quarter- to one-half-inch, 27-gauge needle and a tuberculin sy-
ringe. The tuberculin should be injected just beneath the sur-
face of the skin, with the needle bevel upward or downward
(130). A discrete, pale elevation of the skin (a wheal) 6 to 10
mm in diameter should be produced when the injection is
done correctly. If it is recognized that the first test was im-
properly administered, another test dose can be given at once,
selecting a site several centimeters away from the original in-
jection. A note in the record should indicate the site chosen
for the second test.
Tests should be read between 48 and 72 h after injection,
when the induration is maximum. Tests read after 72 h tend to
underestimate the true size of induration. Reading should be
performed in a good light, with the forearm slightly flexed at
the elbow. The basis of reading is the presence or absence of
induration, which may be determined by inspection (from a
side view against the light as well as by direct light) and by pal-
pation. For standardization, the diameter of induration should
be measured transversely to the long axis of the forearm and
recorded in millimeters (130, 131). The absence of induration
should be recorded as “0 mm,” not “negative.” Interobserver
variability may be decreased by using the ball-point pen
method of Sokal to measure induration (132, 133).
The multiple puncture test introduces tuberculin into the
skin either by puncture with an applicator with points coated
with dried tuberculin or by puncturing through a film of liquid
tuberculin. All multiple puncture tests presently available use
concentrated tuberculin. The quantity of tuberculin intro-
duced into the skin by the multiple puncture test cannot be
precisely controlled. For these reasons, multiple-puncture
tests are not as reliable as the Mantoux method of skin testing
(123) and should not be used as a diagnostic test. If a multiple
puncture test has been placed, the test should be repeated us-
ing the Mantoux method, regardless of the result of the multi-
ple puncture test unless there is vesiculation. In this case, the
test should be considered positive and no Mantoux skin test
placed. For each tuberculin test, a record should be made of
the technique of administration (Mantoux or multiple-punc-
ture), the kind and dose of tuberculin, and the size of reaction
in millimeters of induration.
D. Interpretation of Skin Test Reactions
To interpret the tuberculin skin test appropriately, one must
understand the sensitivity and specificity of the test as well as
the positive and negative predictive value of the test. The sen-
sitivity of a test is the percentage of people with the condition
who have a positive test. If false-negative results are uncom-
mon, the sensitivity is high. The PPD skin test has a reported
false-negative rate of 25% during the initial evaluation of per-
sons with active tuberculosis (134). This high false-negative
rate appears to be due to poor nutrition and general health,
overwhelming acute illness, or immunosuppression.
Immunosuppression can be either specific, which may be
seen early during disease, or nonspecific, which can be the re-
sult of medications, malignancy, or HIV infection (135). Be-
cause of the low sensitivity of the test, especially in acutely ill
patients and those who are infected with HIV, the tuberculin
test cannot be used to eliminate the possibility of active tuber-
culosis (136). Other factors that may result in a false-negative
test are shown in Table 5.
Vaccination with live-attenuated virus can cause suppres-
sion of the PPD response in patients known to be infected
with M. tuberculosis. Live-attenuated vaccines that may cause
false-negative PPD results are measles, mumps, rubella, oral
polio, varicella, yellow fever, BCG, and oral typhoid (TY21a).
This suppression does not appear within the first 48 h after
measles vaccination, so the Advisory Committee on Immuni-
zation Practices recommends that tuberculin testing be done
either on the same day as vaccination with live virus or 4–6 wk
later (137–140).
The specificity of the test is the percentage of people with-
out the condition who have a negative test. False-positive re-
sults decrease the specificity of a test. False-positive tuberculin
tests occur in individuals who have been infected with other
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mycobacteria, including vaccination with BCG. Some antigens
in PPD are shared with the other mycobacteria (141, 142) and
thus can elicit a skin test response. These cross-reactions tend
to result in smaller amounts of induration than reactions due
to M. tuberculosis, but the overlap may be considerable in ar-
eas of the world where the other mycobacteria are common
(136). In these populations, the specificity of the test is highly
dependent on the criterion used to define a “positive” test.
Thus, the specificity of the test can be improved by progres-
sively increasing the cut point for positivity.
In any population, the likelihood that a positive test repre-
sents a true infection is influenced by the prevalence of infec-
tion with M. tuberculosis. Table 6 shows how the prevalence of
infection influences the predictive value of a positive tubercu-
lin test (positive predictive value). The tuberculin skin test has
a specificity of approximately 99% in populations that have no
other mycobacterial exposures or BCG vaccination, but the
specificity decreases to 95% in populations where cross-reac-
tivity with other mycobacteria is common. The general popu-
lation of the United States as a whole currently has an esti-
mated M. tuberculosis infection rate of 5–10%, thus causing
the tuberculin skin test to have a low positive predictive value.
Children entering school in many areas of the country have a
0.1–1% likelihood of being infected. The yearly incidence of
new tuberculosis infection in the general U.S. population with-
out known exposure to tuberculosis is estimated to be 0.1–
0.01%. Therefore, screening of groups without a known or
likely exposure to M. tuberculosis is not recommended. In
these groups, a false-positive result is more likely than a true-
positive result.
In contrast, among persons who have been in close contact
to individuals with infectious tuberculosis, there is a 25–50%
chance of being infected with M. tuberculosis. Likewise, in
high-prevalence countries, adults have a similarly high preva-
lence of infection. In such individuals or populations, the tu-
berculin skin test is highly specific and a positive test is highly
likely to indicate tuberculosis infection.
On the basis of the sensitivity, specificity, and the preva-
lence of tuberculosis in different groups, three cut points have
been recommended for defining a positive tuberculin reaction.
For individuals who are at great risk of developing tuberculo-
sis disease if they become infected with M. tuberculosis (143),
a cut point of > 5 mm is recommended. Reactions in persons
who have had recent close contact with tuberculosis and in
persons with abnormal chest radiographs consistent with tu-
berculosis are more likely to represent infection with M. tuber-
culosis than cross-reactions. Persons who are immunosup-
pressed because of disease (e.g., HIV infection) or drugs (e.g.,
corticosteroids) are more likely to progress to tuberculosis dis-
ease if they are infected with M. tuberculosis. Therefore, using
a lower cut point (e.g., 5 mm) for separating positive from neg-
ative reactions is appropriate in these groups. This will ensure
that few persons infected with M. tuberculosis will be classified
as having negative reactions, although a few persons not in-
fected with tubercle bacilli will be classified as having positive
reactions.
A cut point of > 10 mm is suggested for individuals who
have normal or mildly impaired immunity and a high likeli-
hood of being infected with M. tuberculosis but are without
other risk factors that would increase their likelihood of devel-
oping active disease (Table 7). In addition to those groups
listed, other high-prevalence populations may be identified lo-
cally.
Persons who are not likely to be infected with M. tuberculo-
sis should generally not be tuberculin tested since the predic-




Factors related to the person being tested
Infections
Viral (measles, mumps, chicken pox, HIV)
Bacterial (typhoid fever, brucellosis, typhus, leprosy, pertussis, overwhelming 
tuberculosis, tuberculous pleurisy)
Fungal (South American blastomycosis)
Live virus vaccinations (measles, mumps, polio, varicella)
Metabolic derangements (chronic renal failure)
Low protein states (severe protein depletion, afibrinogenemia)
Diseases affecting lymphoid organs (Hodgkin’s disease, lymphoma, chronic
leukemia, sarcoidosis)
Drugs (corticosteroids and many other immumosuppressive agents)
Age (newborns, elderly patients with “waned” sensitivity)
Stress (surgery, burns, mental illness, graft-versus-host reactions)
Factors related to the tuberculin used




Adsorption (partially controlled by adding Tween 80)
Factors related to the method of administration
Injection of too little antigen
Subcutaneous injection
Delayed administration after drawing into syringe
Injection too close to other skin tests
Factors related to reading the test and recording results
Inexperienced reader
Conscious or unconscious bias
Error in recording
TABLE 6
POSITIVE PREDICTIVE VALUE OF A TUBERCULIN TEST
Prevalence of TB infection
(%)
Positive Predictive Value










HIGH-PREVALENCE AND HIGH-RISK GROUPS
High-prevalence Groups High-risk Groups
Persons born in countries with high Children less than 4 yr of age
prevalence of TB Persons with HIV coinfection
Groups with poor access to health care Persons who are close contacts of
Persons who live or spend time in persons with infectious TB
certain facilities (e.g., nursing homes, Persons whose tuberculin skin test
correctional institutions, homeless results converted to positive 
shelters, drug treatment centers) in the past 1–2 yr
Persons who inject drugs Persons who have chest radiographs
suggestive of old TB
Persons with certain medical
conditions*
* Diabetes mellitus, silicosis, prolonged therapy with corticosteroids, immunosuppressive
therapy, leukemia, Hodgkin’s disease, head and neck cancers, severe kidney disease, certain
intestinal conditions, malnutrition (143).
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poor. However, if a skin test is done, e.g., at entry into a work
site where some risk of exposure to tuberculosis is anticipated
and a longitudinal tuberculin testing program is in place, a
higher cut point of > 15 mm is suggested in order to improve
the specificity of the test (136) (for additional information,
please refer to the ATS Supplement: Targeted tuberculin test-
ing and treatment of latent tuberculosis infection. Am. J.
Respir. Crit. Care Med. 2000;161:S221–S247). These guidelines
are summarized in Table 8.
E. Boosted Reactions and Serial Tuberculin Testing
In most individuals, PPD skin test sensitivity persists through-
out life. However, over time, the size of the skin test may de-
crease and may disappear. If PPD is administered to infected
individuals whose skin tests have waned, the reaction of the
initial test may be small or absent; however, there may be an
accentuation of response on repeated testing. This is called the
“booster effect” and can be misinterpreted as a skin test con-
version. Boosted reactions also are particularly common in in-
dividuals exposed to other mycobacteria or who have been
vaccinated with BCG. If repeated tuberculin testing is antici-
pated, as in health care workers, for example, a two-step
method is recommended. In this method, persons who have a
negative initial PPD skin test undergo a second tuberculin test
1–3 wk after the first. The results from the second test should
be considered to be the “correct” result, i.e., those individuals
with a positive reaction on the second test should be consid-
ered to be previously infected, and those with a negative reac-
tion on the second test should be considered uninfected. In
these uninfected persons, a positive result on any future PPD
skin test should be interpreted as a skin test conversion (144).
Repeated skin testing with tuberculin will not induce a posi-
tive skin test reaction in individuals who have no cellular im-
munity to the antigens in PPD (145).
F. Previous Vaccination with BCG
Immunization with bacillus Calmette–Guerin (BCG) is cur-
rently used in many parts of the world as a means of pre-
venting tuberculosis. BCG is named after the two French in-
vestigators responsible for developing the vaccine from an
attenuated strain of M. bovis. Millions of people around the
world have been vaccinated with BCG, but even so, the effi-
cacy of the vaccine is uncertain. There are ample data indicat-
ing that BCG vaccine protects against disseminated tuberculo-
sis and meningitis in children (146). However, the protection
afforded by BCG against pulmonary disease in both children
and adults is not proven (147). Interestingly, skin test reactiv-
ity resulting from vaccination does not correlate with protec-
tion against tuberculosis (148–150). Genetic variability of the
subjects vaccinated, the nature of the mycobacteria endemic
in different parts of the world, the use of different strains of
BCG for immunization, and the use of different doses of vac-
cine and different schedules of immunization may all contrib-
ute to this variability in efficacy (151).
There is no reliable method of distinguishing tuberculin re-
actions caused by vaccination with BCG from those caused by
natural mycobacterial infections. It is usually prudent to con-
sider “positive” reactions to 5 TU of PPD tuberculin in BCG-
vaccinated persons as indicating infection with M. tuberculosis,
especially among persons from countries with a high preva-
lence of tuberculosis. There are several reasons for not assum-
ing that a large reaction to tuberculin is due to BCG vaccina-
tion: (1) tuberculin test conversion rates after vaccination may
be much less than 100%; (2) the mean reaction size among per-
sons who have received BCG is often , 10 mm; and (3) tuber-
culin sensitivity tends to wane after vaccination. Although a
positive tuberculin skin test due to BCG vaccination can wane
over time, it can be “boosted” by serial testing. Because most
persons who have received BCG are from high-prevalence ar-
eas of the world, it is important that vaccinated persons who
have a positive reaction to a tuberculin skin test be evaluated
for tuberculosis and treated accordingly (152, 153).
G. Definition of Skin Test Conversions
It may be difficult to determine the relevance of a tuberculin
skin test if there are two readings with different degrees of indu-
ration recorded. Because there are unavoidable errors in even
the most carefully performed tests, small increases in reaction
size may not be meaningful. For persons with negative tubercu-
lin skin test reactions who undergo repeat skin testing (e.g.,
health care workers), an increase in reaction size of 10 mm or
more within a period of 2 yr should be considered a skin test
conversion indicative of recent infection with M. tuberculosis.
In some individuals who have been infected with nontuber-
culous mycobacteria or have undergone BCG vaccination, the
skin test may show some degree of induration. For these indi-
viduals, a conversion to “positive” is defined as an increase in
induration by 10 mm on subsequent tests.
H. Anergy Testing in Individuals Infected with HIV
HIV-infected persons may have a compromised ability to react
to tuberculin skin tests because of cutaneous anergy (26, 154).
TABLE 8
GUIDELINES FOR DETERMINING A POSITIVE TUBERCULIN SKIN TEST REACTION
Induration > 5 mm Induration > 10 mm Induration > 15 mm
HIV-positive persons Recent arrivals (, 5 yr) from high-prevalence countries Persons with no risk
factors for TB
Recent contacts of TB case Injection drug users
Residents and employees* of high-risk congregate settings:
prisons and jails nursing homes and other health care facilities, residential facilities 
for AIDS patients, and homeless shelters
Mycobacteriology laboratory personnel
Fibrotic changes on chest radiograph
consistent with old TB
Persons with clinical conditions that make them high-risk: silicosis diabetes mellitus, 
chronic renal failure, some hematologic disorders (e.g., leukemias and lymphomas), 
other specific malignancies (e.g., carcinoma of the head or neck and lung),
weight loss of . 10% of ideal body weight, gastrectomy, jejunoileal bypass
Patients with organ transplants and other 
immunosuppressed patients
(receiving the equivalent of . 15 mg/d
Prednisone for . 1 mo)
Children , 4 yr of age or infants, children, and adolescents exposed to adults in
high-risk categories
* For persons who are otherwise at low risk and are tested at entry into employment, a reaction of . 15 mm induration is considered positive.
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Anergy testing is the assessment of response to skin test anti-
gens to which a cell-mediated delayed-type hypersensitivity
(DTH) is expected. An impaired DTH response is directly re-
lated to decreasing CD41 T cell counts and, therefore, as HIV
infection causes decreasing CD41 counts, the incidence of an-
ergy increases. Some studies have shown that anergy testing
provides additional prognostic information for HIV complica-
tions and death after stratification of CD4+counts (155, 156).
Skin tests to identify anergy are placed by intradermal in-
jection, using the Mantoux method, but there is no standard
convention for classifying a positive response. Individuals who
mount a response to any antigen are considered to have rela-
tively intact cellular immunity, whereas those who cannot
mount any responses are considered “anergic.” The PPD tu-
berculin test elicits a DTH response and therefore people with
a “positive” PPD are not anergic (157). Unfortunately, the va-
lidity of anergy testing in the diagnosis of tuberculosis is ques-
tionable. First, selective nonreactivity to PPD is a recognized
phenomenon (158). Second, mumps reactivity may remain
after loss of PPD reactivity (159). Third, PPD boosting can oc-
cur in people with an initial positive reaction to control anti-
gens (160). Because of these findings, a positive DTH response
to antigens other than PPD is not proof that a negative PPD
applied at the same time indicates absence of TB infection.
Conversely, failure to respond to anergy tests does not mean
that an individual will not respond to PPD. In addition, serial
anergy testing among HIV-infected persons has shown unpre-
dictable variations over time (159), and how much variation is
due to changes in immune competence and how much is due
to differences in the tests themselves cannot be determined
(157). Thus, anergy testing is not recommended for use in iden-
tifying tuberculosis infection in individuals, including those
who are HIV infected (157).
VII. CLASSIFICATION OF PERSONS EXPOSED
TO AND/OR INFECTED WITH
Mycobacterium tuberculosis
This classification is based on the broad host–parasite rela-
tionships as described by exposure history, infection, and dis-
ease. It is intended mainly as an operational framework for
public health programs. The HIV status of an individual should
be known, since HIV infection may change the approach to di-
agnosis and therapy for tuberculosis.
0. No tuberculosis exposure, not infected. Persons in this
class have no history of exposure and a negative reaction to
the tuberculin skin test (if tested).
1. Tuberculosis exposure, no evidence of infection. Persons
in class 1 do have a history of exposure but have a negative re-
action to the tuberculin skin test. Action taken for persons in
this class depends mainly on the degree and recency of expo-
sure to M. tuberculosis, as well as the immune status of the ex-
posed person. If there has been significant exposure within 3 mo,
a follow-up skin test should be performed 10 wk after the last
exposure and in the interim, treatment of latent tuberculosis
infection should be considered, especially for children less than
15 yr of age and persons with HIV infection.
2. Latent tuberculosis infection, no disease. Persons in class
2 have a positive reaction to the tuberculin skin test (indicate
mm in duration), negative bacteriologic studies (if done), and
no clinical, bacteriological, or radiographic evidence of active
tuberculosis. Treatment of latent tuberculosis infection may
be indicated for some persons in this group.
Chemotherapy status
Never received therapy
Currently receiving chemotherapy (date and regimen)
Therapy complete (dates and prescribed course of ther-
apy)
Therapy incomplete (dates and regimen)
3. Tuberculosis, clinically active. Class 3 includes all pa-
tients with clinically active tuberculosis whose diagnostic pro-
cedures are complete. If the diagnosis is still pending, the per-
son should be classified as a tuberculosis suspect (Class 5). To
fit into Class 3, a person must have clinical, bacteriological,
and/or radiographic evidence of current tuberculosis. This is
established most definitively by isolation of M. tuberculosis. A
person who had past tuberculosis and who also currently has
clinically active disease belongs in Class 3. A person remains
in Class 3 until treatment for the current episode of disease is












The predominant site should be listed. Other sites may also









Nucleic acid amplification (date)
Culture (date)
Susceptibility results with method and concentrations
used (date)






Stable or worsening or improving
Tuberculin skin test reaction
Positive (mm induration)
Negative (mm induration)
4. Tuberculosis: not clinically active. This classification is
defined by a history of previous episode(s) of tuberculosis or
abnormal stable radiographic findings in a person with a posi-
tive reaction to tuberculin skin test (indicate mm induration),
negative bacteriologic studies (if done), and no clinical and/or
radiographic evidence of current disease. Persons in Class 4
may never have received chemotherapy, may be receiving
treatment for latent infection, or may have completed a previ-
ously prescribed course of chemotherapy. If current clinically
active disease has not been ruled out, especially in persons not
adequately treated in the past, this person should be classified
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as a tuberculosis suspect (Class 5) until diagnostic evaluation
permits classification as Class 3 or Class 4.
5. Tuberculosis suspect (diagnosis pending). Persons should
be so classified when a diagnosis of tuberculosis is being con-
sidered, whether or not treatment has been started, until diag-
nostic procedures have been completed. Persons should not
remain in this class for more than 3 mo. When diagnostic pro-
cedures have been completed, the person should be placed in
one of the preceding classes.
VIII. REPORTING OF TUBERCULOSIS
By law and regulation, a case of active tuberculosis in the
United States must be reported to the local health depart-
ment. Reporting is essential for action by the tuberculosis
control program at local, state, and national levels, and for un-
derstanding of the magnitude and the distribution of the tu-
berculosis problem.
Reporting makes the resources of the health department
available to assist the physician in the proper management of
the case. Public health services are available for epidemiologic
evaluation, including the identification and the examination of
source cases and contacts. Therefore, reporting of tuberculosis
suspects promptly (prior to bacteriologic confirmation) is im-
portant. Health department laboratory and radiographic ser-
vices and consultation are generally available to assist the phy-
sician in carrying out responsibilities in the treatment of
tuberculosis (161). All positive smear, culture, susceptibility,
and nucleic acid amplification results should be reported to
the health department and treating physicians within one
working day. Ideally, the actual M. tuberculosis culture should
be sent to the state laboratory so that genotyping can be per-
formed when needed.
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